Immutep (IMM) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional land owners, introduction of board members and key executives, and an overview of key programs and agenda.

• Quorum confirmed, voting procedures and card system explained for shareholders, proxies, and visitors.

• Notice of meeting confirmed as properly distributed and taken as read.

Financial performance review

• Ended FY2025 with AUD 129.7 million in cash and term deposits; cash and equivalents as of September 2025 reported at approximately AUD 109.9 million, ensuring runway through end of CY2026.

• FY25 revenue and other income reached AUD 10.3 million, up from AUD 7.8 million in FY24.

• R&D and IP expenses increased to AUD 61.4 million in FY25 due to expanded clinical trial activity.

• Net loss for FY25 was AUD 61.4 million, compared to AUD 42.7 million in FY24.

• Maintained prudent cost management, focusing on R&D over G&A expenses, and expanded team to support development.

Board and executive committee updates

• Dr. Stephan Winckels appointed Chief Medical Officer; Christian Mueller promoted to Chief Development Officer.

• Company added to S&P/ASX 300 Index after September 2024 review, enhancing market visibility and investor confidence.

• Expanded team with additional experienced staff to support development strategy.